Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 16/20 | 0.46 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.46 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.38 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.38 |
| ▸ | TAS2R8 | Q9NYW2 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15528218 | 0.86 | LRRK2 (0.44) | KCNH2GRIN2BBRD4DDB1CRBN | |
| SCHEMBL17458889 | 0.75 | KCNH2 (0.41) | KCNH2GRIN2BBRD4DDB1CRBN | |
| SCHEMBL17076762 | 0.74 | KCNH2 (0.59) | KCNH2GRIN2BTAS2R8 | |
| SCHEMBL17458959 | 0.73 | KLKB1 (0.42) | — | |
| SCHEMBL17076745 | 0.73 | KLKB1 (0.42) | BRD4 | |
| SCHEMBL17076657 | 0.73 | CREBBP (0.41) | — | |
| SCHEMBL17076701 | 0.72 | GRIN1 (0.35) | GRIN2B | |
| SCHEMBL15652624 | 0.72 | BRD4 (0.40) | GRIN2BBRD4 | |
| SCHEMBL17459093 | 0.71 | RAB9A (0.48) | — | |
| SCHEMBL18157953 | 0.71 | KCNH2 (0.46) | KCNH2GRIN2BBRD4DDB1CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220119371-A1 | COMPOUND, COMPOSITIONS, AND METHODS | DENALI THERAPEUTICS INC. (US) | 2022-04-21 | — | — | US | disclosed |
| US-11214565-B2 | Compound, compositions, and methods | DENALI THERAPEUTICS INC. (US) | 2022-01-04 | — | — | US | disclosed |
| US-10752624-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2020-08-25 | — | — | US | disclosed |
| US-20180327391-A1 | COMPOUND, COMPOSITIONS, AND METHODS | DENALI THERAPEUTICS INC. | 2018-11-15 | — | — | US | disclosed |
| US-20180305356-A1 | NOVEL KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2018-10-25 | — | — | US | disclosed |
| US-10000482-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2018-06-19 | — | — | US | disclosed |
| US-20170226081-A1 | GLUCOSE TRANSPORT INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-08-10 | — | — | US | disclosed |
| US-20170226081-A1 | GLUCOSE TRANSPORT INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-08-10 | — | — | US | disclosed |
| US-20170226081-A1 | GLUCOSE TRANSPORT INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-08-10 | — | — | US | disclosed |
| US-20170210738-A1 | GLUCOSE TRANSPORT INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-07-27 | — | — | US | disclosed |
| EP-3172194-A1 | GLUCOSE TRANSPORT INHIBITORS | Bayer Pharma Aktiengesellschaft (DE) | 2017-05-31 | — | — | EP | disclosed |
| EP-3172192-A1 | GLUCOSE TRANSPORT INHIBITORS | Bayer Pharma Aktiengesellschaft (DE) | 2017-05-31 | — | — | EP | disclosed |
| US-9637491-B2 | Pyrazolo[4,3-D]pyrimidines as kinase inhibitors | ORIGENIS GMBH (DE) | 2017-05-02 | — | — | US | disclosed |
| WO-2016012474-A1 | GLUCOSE TRANSPORT INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-01-28 | — | — | WO | disclosed |
| WO-2016012474-A1 | GLUCOSE TRANSPORT INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-01-28 | — | — | WO | disclosed |
| WO-2016012481-A1 | GLUCOSE TRANSPORT INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-01-28 | — | — | WO | disclosed |
| WO-2016012481-A1 | GLUCOSE TRANSPORT INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-01-28 | — | — | WO | disclosed |
| US-20150266882-A1 | PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2015-09-24 | — | — | US | disclosed |
| US-20150259340-A1 | NOVEL KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2015-09-17 | — | — | US | disclosed |
| WO-2012062783-A1 | PYRAZOLE AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180327391-A1 | COMPOUND, COMPOSITIONS, AND METHODS | LRRK2, PARK7, MAPT | KCNH2 2999/4885GRIN2B 147/4885BRD4 2777/4885 |
| US-20150259340-A1 | NOVEL KINASE INHIBITORS | LRRK2, MYLK2, MYLK | KCNH2 1965/4885GRIN2B 1002/4885BRD4 2023/4885 |
| US-20220119371-A1 | COMPOUND, COMPOSITIONS, AND METHODS | LRRK2, PARK7, SNCA | KCNH2 3011/4885GRIN2B 166/4885BRD4 2744/4885 |
| US-20150266882-A1 | PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS | LRRK2, MYLK2, MYLK | KCNH2 1736/4885GRIN2B 1247/4885BRD4 1732/4885 |
| US-20180305356-A1 | NOVEL KINASE INHIBITORS | LRRK2, MYLK2, MYLK | KCNH2 1965/4885GRIN2B 1002/4885BRD4 2023/4885 |
| US-11214565-B2 | Compound, compositions, and methods | LRRK2, PARK7, MAPT | KCNH2 2999/4885GRIN2B 147/4885BRD4 2777/4885 |
| US-20170226081-A1 | GLUCOSE TRANSPORT INHIBITORS | SLC2A1, SLC2A2, SLC2A4 | KCNH2 1396/4885GRIN2B 1088/4885BRD4 3594/4885 |
| US-10000482-B2 | Kinase inhibitors | LRRK2, MYLK2, MYLK | KCNH2 2115/4885GRIN2B 1100/4885BRD4 1774/4885 |
| US-10752624-B2 | Kinase inhibitors | LRRK2, MYLK2, MYLK | KCNH2 2115/4885GRIN2B 1100/4885BRD4 1774/4885 |
| US-20170210738-A1 | GLUCOSE TRANSPORT INHIBITORS | SLC2A1, SLC2A2, SLC2A4 | KCNH2 1000/4885GRIN2B 1207/4885BRD4 4438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.